Biocon's conosldidated net profit surged 154.24% to Rs 344.50 crore in Q4 FY25, compared with Rs 135.50 crore in Q4 FY24.

The global race for weight loss solutions has firmly arrived in India—bringing with it hope, hype, and a host of unanswered ...

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it has signed a ...

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert breaks down its benefits, downsides and the need for responsible rollout in a ...

Our global Injectables business is delivering a solid revenue performance, driven by each of our three geographies ...

Thank you for joining us today for the Dr. Reddy's earnings conference call covering the quarter and full year ended March 31, 2025. We appreciate your time and participation. Joining us today is the ...

AZ and Regeneron will collaborate on finding small-molecule drugs directed against ... Nordisk's once-daily injectable weight loss therapy Saxenda (liraglutide) has been a slow grower, but is ...